Hot Features
Premium
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0.00 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Vicapsys Life Sciences Inc (PK) | VICP | OTCMarkets | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.444 | 07:04:40 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.444 | 0.444 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0.00 | - | 0.444 - 3.00 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 0.444 | USD |
Vicapsys Life Sciences Inc (PK) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 13.87M | 31.24M | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Vicapsys Life Sciences (PK) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 12/27/2023 | 13:18 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/14/2023 | 13:22 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 8/14/2023 | 10:11 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 8/09/2023 | 15:00 | Edgar (US Regulatory) | Form DEF 14C - Other definitive information statements |
| 7/28/2023 | 15:56 | Edgar (US Regulatory) | Form PRE 14C - Other preliminary information statements |
| 7/13/2023 | 12:24 | Edgar (US Regulatory) | Form D - Notice of Exempt Offering of Securities |
| 7/03/2023 | 11:41 | Edgar (US Regulatory) | Form S-1 - General form for registration of securities under.. |
| 6/30/2023 | 16:26 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VICP Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.5777 | 0.9899 | 0.444 | 0.6162802 | 1,315 | -0.1337 | -23.14% |
| 3 Months | 2.00 | 2.25 | 0.444 | 1.11 | 644 | -1.56 | -77.80% |
| 6 Months | 2.75 | 2.75 | 0.444 | 1.19 | 520 | -2.31 | -83.85% |
| 1 Year | 1.03 | 3.00 | 0.444 | 1.35 | 446 | -0.586 | -56.89% |
| 3 Years | 1.11 | 8.00 | 0.0001 | 1.71 | 435 | -0.666 | -60.00% |
| 5 Years | 2.40 | 8.00 | 0.0001 | 1.75 | 365 | -1.96 | -81.50% |
Vicapsys Life Sciences (PK) Description
| ViCapsys is a development stage biotechnology company that is advancing a proprietary localized immune modulator. ViCapsys's technology allows physicians to control the body's immune system in regional areas around an implant, which reduces the risk of transplant rejection or fibrotic overgrowth due to foreign body recognition. The product offers wide ranging benefits in multiple surgical applications including, organ transplants, medical device implantations, and wound healing, without the need for systemic immune suppression. ViCapsys is currently investigating three initial pipeline products treating type 1 diabetes, post-surgical abdominal adhesion formation, and post-trauma keloid formation. The company intends to develop and license other technologies related to immune modulation going forward. |
